Form 4: Ultragenyx Officer Sells Shares for Tax Withholding

Ultragenyx Pharmaceutical Inc.'s SVP, Chief Accounting Officer, Theodore Alan Huizenga, sold 64 shares of common stock to cover tax withholdings from RSU vesting.

Summary

• Theodore Alan Huizenga, SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc. (RARE), reported a transaction.
• On September 18, 2025, Mr. Huizenga sold 64 shares of common stock at a price of $29.17 per share.
• The sale was conducted to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Mr. Huizenga beneficially owns 50,242 shares of common stock, which includes previously reported shares underlying RSUs subject to vesting conditions.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine sale for tax withholding purposes, not indicative of positive or negative sentiment towards the company's prospects. The officer retains a substantial holding.

Positives

• The transaction is a routine, non-discretionary sale for tax withholding purposes, not indicative of a lack of confidence in the company's future.
• The officer retains a significant beneficial ownership of 50,242 shares, maintaining alignment with shareholder interests.

Negatives

• A minor reduction in the direct beneficial ownership of common stock by a key executive.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, common across all industries when executives receive equity compensation that vests and requires tax withholding. It does not inherently reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• This type of transaction (sale for tax withholding) is a standard practice for executives receiving equity compensation across publicly traded companies.
• It is not comparable to specific company projects or results, but rather a common mechanism for managing RSU vesting.
• No specific comparable companies, projects, or results are mentioned in the filing.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related sale, not a discretionary divestment. The officer's continued significant holding aligns interests.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The Form 4 filing details a routine, non-discretionary sale of a small number of shares by an executive to cover tax obligations related to RSU vesting. This type of transaction is common and does not typically signal a change in the company's fundamentals or the executive's confidence. The executive retains a substantial beneficial ownership, suggesting continued alignment with shareholder interests. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as there is no new information to warrant a change in investment thesis.

Keywords

Ultragenyx Pharmaceutical Inc., RARE, Form 4, Insider Transaction, Stock Sale, Theodore Alan Huizenga, RSU Vesting, Tax Withholding, Officer Transaction, Equity Compensation